Head and neck squamous cell carcinoma (HNSCC) is a challenging cancer to treat and cure. A great proportion of patients present with advanced disease and appropriate treatment options include surgical resection with adjuvant radiotherapy (RT) or chemoradiotherapy (CRT), radical concurrent CRT or RT with monoclonal antibody cetuximab. Despite improved outcomes with CRT, overall prognosis is still unsatisfactory and treatment-related toxicity is a matter of major importance. To obtain improved outcomes and mitigate disease recurrence, current research is focused on novel molecular targeted agents, immunotherapy and discovery of predictive markers. Head and Neck Cancer (EXTREME) study, the addition of cetixumab to platinum-based chemotherapy with fluorouracil was shown to improve overall survival (OS), progression-free survival (PFS) and response rates. afatinib compared with methotrexate (2.6 versus 1.7 months, hazard ratio (HR) 0.8; p=0.03). In addition, it showed improvement in tumour shrinkage and response rate in favour of afatinib. 10 The difference in PFS of 0.9 months is of unclear significance and unlikely to lead to drug approval. However, this study is important, as it is the second study since the EXTREME trial that showed benefit of a novel agent in HNSCC and the first study to demonstrate an active oral targeted agent in HNSCC. Of note, subgroup analysis showed a benefit primary seen in EGFR-naïve patients, suggesting a degree of cross-resistance that was not seen in phase II studies. 9 Ongoing studies evaluating adjuvant afatinib in locally advanced HNSCC after chemoradiotherapy (LUX-Head and Neck-2) will hopefully clarify the effectiveness of afatinib; 11 until then, active search of predictive biomarkers might lead to identification of specific groups of patients with greater benefit.
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Despite advances in multimodality treatment, the 5-year survival rate of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) does not exceed 40-50% and survival rates for recurrent or metastatic disease (R/M) remain dismal. 1, 2 Low survival rates in combination with significant toxicities caused by current treatment strategies used in HNSCC emphasise the necessity for new treatment options.
For patients with recurrent or metastatic disease, recommended treatment is cisplatin-based chemotherapy ± cetuximab for fit patients and single agent chemotherapy (methotrexate) or cetuximab for patients with poor performance status (PS), albeit with limited efficacy. Head and Neck Cancer (EXTREME) study, the addition of cetixumab to platinum-based chemotherapy with fluorouracil was shown to improve overall survival (OS), progression-free survival (PFS) and response rates. 6 However, cetuximab has demonstrated modest response rates when used as monotherapy. 7 Afatinib, an oral irreversible ErbB family blocker that inhibits all kinase-active members (EGFR, HER2 and HER4), which is currently approved for the treatment of EGFR mutated non-small-cell lung cancer, 8 has been shown similar antitumour effects compared with cetuximab in R/M HNSCC in a phase II trial. shrinkage and response rate in favour of afatinib. 10 The difference in PFS of 0.9 months is of unclear significance and unlikely to lead to drug approval. However, this study is important, as it is the second study since the EXTREME trial that showed benefit of a novel agent in HNSCC and the first study to demonstrate an active oral targeted agent in HNSCC. Of note, subgroup analysis showed a benefit primary seen in EGFR-naïve patients, suggesting a degree of cross-resistance that was not seen in phase II studies. 9 Ongoing studies evaluating adjuvant afatinib in locally advanced HNSCC after chemoradiotherapy (LUX-Head and Neck-2) will hopefully clarify the effectiveness of afatinib; 11 until then, active search of predictive biomarkers might lead to identification of specific groups of patients with greater benefit.
Another rationale for improvement of treatment strategies in HNSCC is to overcome resistance to cetuximab, which might lead to tumour progression after initial clinical response. One proposed mechanism of de novo or acquired resistance in HNSCC is HER3 activation.
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MEHD7945A is a monoclonal antibody that simultaneously blocks ligand binding to EGFR and HER3 and inhibits signalling by all major liganddependent HER family members. 13 It has shown superior preclinical activity compared with mono-specific HER antibodies, particularly in HNSCC and has displayed activity in cetuximab-resistant models. has demonstrated response rates as high as 20 % albeit with greater toxicity (grade ≥3 AEs in 17 % of patients). 19 Of note, some responses are durable, but specific biomarkers are lacking.
It is important to emphasise that HNSCC is currently divided into two distinct entities in terms of aetiology and clinical behaviour. Tobacco/ alcohol consumption-associated HNSCC is described as human papilloma virus (HPV) negative (HPV-) subset and is usually p16
negative. Infection with high-risk HPVs is linked to a growing proportion of oropharyngeal cancers (HPV positive [HPV+] HNSCC). HPV+ HNSCC is associated with a better prognosis and might require different treatments. 20 In addition, HPV status has prognostic significance in recurrent/metastatic setting as well. 21, 22 As a result, current clinical trials attempt to assess benefit of investigational agents separately in HPV-and HPV+ HNSCC. In the LUX-Head and Neck 1 study, HPV-patients were found to have greater benefit from afatinib therapy. 10 The chemotherapy was restricted to p16-negative patients 23 while the analysis of the EXTREME study showed that both HPV+ and HPVpatients derive benefit from the addition of cetuximab to platinum/5-FU chemotherapy. 6 Anti-PDL-1 antibodies had conflicting results, with
MEDI4736 showing greater benefit in HPV-tumours 18 while MK3475 demonstrated equal efficacy in both. 19 Finally, intensification of chemotherapy treatment protocols is another rationale for potential improvement of outcomes in HNSCC. However, treatment-related toxicity in HNSCC remains a matter of major importance. Final analysis of the AIO trial has shown that addition of docetaxel to EXTREME regimen of cisplatin, 5-FU and cetuximab not only does not improve outcome compared with EXTREME regimen but also increases GI toxicity and infections. 6, 24 In conclusion, the prognosis of patients with R/M HNSCC remains dismal. As intensification of chemotherapy protocols carries the risk of unacceptable toxicity: the future lies on the introduction of novel molecular-targeted agents. Identification of predictive biomarkers for patient selection for targeted therapies including immunotherapy is essential. Importantly, future studies should focus on assessing effectiveness of investigational treatments according to HPV status. n
